Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1947 1
1948 1
1949 1
1967 2
1975 2
1976 1
1977 2
1978 4
1979 1
1980 1
1981 4
1982 6
1983 11
1984 10
1985 12
1986 4
1987 8
1988 13
1989 19
1990 54
1991 44
1992 58
1993 45
1994 59
1995 58
1996 49
1997 56
1998 38
1999 46
2000 59
2001 53
2002 40
2003 51
2004 57
2005 71
2006 61
2007 71
2008 81
2009 87
2010 105
2011 93
2012 92
2013 127
2014 176
2015 183
2016 180
2017 200
2018 185
2019 189
2020 262
2021 309
2022 308
2023 328
2024 116

Text availability

Article attribute

Article type

Publication date

Search Results

3,710 results

Results by year

Filters applied: . Clear all
Page 1
Tisagenlecleucel in adult relapsed or refractory follicular lymphoma: the phase 2 ELARA trial.
Fowler NH, Dickinson M, Dreyling M, Martinez-Lopez J, Kolstad A, Butler J, Ghosh M, Popplewell L, Chavez JC, Bachy E, Kato K, Harigae H, Kersten MJ, Andreadis C, Riedell PA, Ho PJ, Pérez-Simón JA, Chen AI, Nastoupil LJ, von Tresckow B, Ferreri AJM, Teshima T, Patten PEM, McGuirk JP, Petzer AL, Offner F, Viardot A, Zinzani PL, Malladi R, Zia A, Awasthi R, Masood A, Anak O, Schuster SJ, Thieblemont C. Fowler NH, et al. Among authors: ho pj. Nat Med. 2022 Feb;28(2):325-332. doi: 10.1038/s41591-021-01622-0. Epub 2021 Dec 17. Nat Med. 2022. PMID: 34921238 Free article. Clinical Trial.
Tisagenlecleucel is an autologous anti-CD19 chimeric antigen receptor-T cell therapy with clinically meaningful outcomes demonstrated in patients with relapsed/refractory (r/r) B-cell lymphoma. In a previous pilot study of tisagenlecleucel in r/r folli …
Tisagenlecleucel is an autologous anti-CD19 chimeric antigen receptor-T cell therapy with clinically meaningful outcomes demonstrated in pat …
The influence of parental practices on child promotive and preventive food consumption behaviors: a systematic review and meta-analysis.
Yee AZ, Lwin MO, Ho SS. Yee AZ, et al. Among authors: ho ss. Int J Behav Nutr Phys Act. 2017 Apr 11;14(1):47. doi: 10.1186/s12966-017-0501-3. Int J Behav Nutr Phys Act. 2017. PMID: 28399881 Free PMC article. Review.

The food consumption behaviors examined include fruits and vegetables consumption, sugar-sweetened beverages, and snack consumption. RESULTS: Results indicate that availability (Healthy: r = .24, p < .001; Unhealthy: r = .34, p < .001) and parental modeling ef

…
The food consumption behaviors examined include fruits and vegetables consumption, sugar-sweetened beverages, and snack consumption. RESULTS …
RNF8 ubiquitylation of XRN2 facilitates R-loop resolution and restrains genomic instability in BRCA1 mutant cells.
Krishnan R, Lapierre M, Gautreau B, Nixon KCJ, El Ghamrasni S, Patel PS, Hao J, Yerlici VT, Guturi KKN, St-Germain J, Mateo F, Saad A, Algouneh A, Earnshaw R, Shili D, Seitova A, Miller J, Khosraviani N, Penn A, Ho B, Sanchez O, Hande MP, Masson JY, Brown GW, Alaoui-Jamali M, Reynolds JJ, Arrowsmith C, Raught B, Pujana MA, Mekhail K, Stewart GS, Hakem A, Hakem R. Krishnan R, et al. Among authors: ho b. Nucleic Acids Res. 2023 Oct 27;51(19):10484-10505. doi: 10.1093/nar/gkad733. Nucleic Acids Res. 2023. PMID: 37697435 Free PMC article.
Mechanistically, RNF8 interacts with XRN2, which is crucial for transcription termination and R-loop resolution. We report that RNF8 ubiquitylates XRN2 to facilitate its recruitment to R-loop-prone genomic loci and that RNF8 deficiency in BRCA1-mutant breast cancer …
Mechanistically, RNF8 interacts with XRN2, which is crucial for transcription termination and R-loop resolution. We report that RNF8 …
Growth hormone releasing hormone signaling promotes Th17 cell differentiation and autoimmune inflammation.
Du L, Ho BM, Zhou L, Yip YWY, He JN, Wei Y, Tham CC, Chan SO, Schally AV, Pang CP, Li J, Chu WK. Du L, et al. Among authors: ho bm. Nat Commun. 2023 Jun 6;14(1):3298. doi: 10.1038/s41467-023-39023-1. Nat Commun. 2023. PMID: 37280225 Free PMC article.
Here, we show GHRH-R is an important regulator of Th17 cell differentiation in Th17 cell-mediated ocular and neural inflammation. We find that GHRH-R is not expressed in naive CD4(+) T cells, while its expression is induced throughout Th17 cell differentiation in vi …
Here, we show GHRH-R is an important regulator of Th17 cell differentiation in Th17 cell-mediated ocular and neural inflammation. We …
Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60).
Pfreundschuh M, Schubert J, Ziepert M, Schmits R, Mohren M, Lengfelder E, Reiser M, Nickenig C, Clemens M, Peter N, Bokemeyer C, Eimermacher H, Ho A, Hoffmann M, Mertelsmann R, Trümper L, Balleisen L, Liersch R, Metzner B, Hartmann F, Glass B, Poeschel V, Schmitz N, Ruebe C, Feller AC, Loeffler M; German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL). Pfreundschuh M, et al. Among authors: ho a. Lancet Oncol. 2008 Feb;9(2):105-16. doi: 10.1016/S1470-2045(08)70002-0. Epub 2008 Jan 15. Lancet Oncol. 2008. PMID: 18226581 Clinical Trial.
Compared with six cycles of CHOP-14, the improvement in 3-year event-free survival was 5.8% (-2.8-14.4) for eight cycles of CHOP-14, 19.3% (11.1-27.5) for six cycles of R-CHOP-14, and 15.9% (7.6-24.2) for eight cycles of R-CHOP-14. 3-year overall survival was 67.7% …
Compared with six cycles of CHOP-14, the improvement in 3-year event-free survival was 5.8% (-2.8-14.4) for eight cycles of CHOP-14, 19.3% ( …
The association between victimization and inflammation: A meta-analysis.
Chen XY, Chan KL, Lo CKM, Ho FK, Leung WC, Ip P. Chen XY, et al. Among authors: ho fk. J Affect Disord. 2023 Feb 15;323:108-122. doi: 10.1016/j.jad.2022.11.063. Epub 2022 Nov 24. J Affect Disord. 2023. PMID: 36435395 Review.
Overall, victimization has a significantly positive association with inflammation, with a small effect size (r = 0.122). Specifically, effect sizes were the largest for TNF-a (r = 0.152), followed by IL-6 (r = 0.119), and CRP (r = 0.084). Additionally, …
Overall, victimization has a significantly positive association with inflammation, with a small effect size (r = 0.122). Specifically …
RNF168 regulates R-loop resolution and genomic stability in BRCA1/2-deficient tumors.
Patel PS, Abraham KJ, Guturi KKN, Halaby MJ, Khan Z, Palomero L, Ho B, Duan S, St-Germain J, Algouneh A, Mateo F, El Ghamrasni S, Barbour H, Barnes DR, Beesley J, Sanchez O, Berman HK, Brown GW, Affar EB, Chenevix-Trench G, Antoniou AC, Arrowsmith CH, Raught B, Pujana MA, Mekhail K, Hakem A, Hakem R. Patel PS, et al. Among authors: ho b. J Clin Invest. 2021 Feb 1;131(3):e140105. doi: 10.1172/JCI140105. J Clin Invest. 2021. PMID: 33529165 Free PMC article.
Using interactome assays, we identified RNF168 interaction with DHX9, a helicase involved in the resolution and removal of R-loops. Mechanistically, RNF168 directly ubiquitylated DHX9 to facilitate its recruitment to R-loop-prone genomic loci. Consequently, loss of …
Using interactome assays, we identified RNF168 interaction with DHX9, a helicase involved in the resolution and removal of R-loops. M …
Preventing ischemia-reperfusion injury by acousto-mechanical local oxygen delivery.
Ho YJ, Hsu HC, Wu BH, Lin YC, Liao LD, Yeh CK. Ho YJ, et al. J Control Release. 2023 Apr;356:481-492. doi: 10.1016/j.jconrel.2023.03.018. Epub 2023 Mar 15. J Control Release. 2023. PMID: 36921723
This cooperation between biomechanical and biochemical stimuli might modulate endothelial metabolism, providing a potential clinical approach to the prevention of I/R injury. Murine hindlimb and cardiac I/R models were used to demonstrate the feasibility of injury p …
This cooperation between biomechanical and biochemical stimuli might modulate endothelial metabolism, providing a potential clinical approac …
Durable Response After Tisagenlecleucel in Adults With Relapsed/Refractory Follicular Lymphoma: ELARA Trial Update.
Dreyling M, Fowler NH, Dickinson M, Martínez-López J, Kolstad A, Butler J, Ghosh M, Popplewell L, Chavez JC, Bachy E, Kato K, Harigae H, Kersten MJ, Andreadis CB, Riedell PA, Ho PJ, Perez-Simon JA, Chen AI, Nastoupil LJ, von Tresckow B, Ferreri AJ, Teshima T, Patten PE, McGuirk JP, Petzer AL, Offner F, Viardot A, Zinzani PL, Malladi R, Paule I, Zia A, Awasthi R, Han X, Germano D, O'Donovan DS, Ramos RJ, Maier HJ, Masood A, Thieblemont C, Schuster SJ. Dreyling M, et al. Among authors: ho pj. Blood. 2024 Jan 9:blood.2023021567. doi: 10.1182/blood.2023021567. Online ahead of print. Blood. 2024. PMID: 38194692 Free article.
Tisagenlecleucel is approved for adults with relapsed/refractory (r/r) follicular lymphoma (FL) in the 3rd-line setting. The primary analysis (median follow-up: 17 months) of the Phase II ELARA trial (ClinicalTrials.gov identifier: NCT03568461) reported high respons …
Tisagenlecleucel is approved for adults with relapsed/refractory (r/r) follicular lymphoma (FL) in the 3rd-line setting. The p …
The abuse liability of ketamine: A scoping review of preclinical and clinical studies.
Le TT, Cordero IP, Jawad MY, Swainson J, Di Vincenzo JD, Jaberi S, Phan L, Lui LMW, Ho R, Rosenblat JD, McIntyre RS. Le TT, et al. Among authors: ho r. J Psychiatr Res. 2022 Jul;151:476-496. doi: 10.1016/j.jpsychires.2022.04.035. Epub 2022 May 10. J Psychiatr Res. 2022. PMID: 35623124 Review.
Clinical and preclinical studies that assessed the abuse potential of (R,S)-ketamine, (S)-ketamine, and (R)-ketamine were screened and assessed for eligibility by two independent reviewers. ...Only 4 preclinical studies evaluated the abuse liability of ketamine enan …
Clinical and preclinical studies that assessed the abuse potential of (R,S)-ketamine, (S)-ketamine, and (R)-ketamine were scre …
3,710 results